What are the general guidelines for stopping apixaban (Eliquis) after six months of treatment for deep vein thrombosis (DVT)?

Discontinuing Apixaban After 6 Months of DVT Treatment

The decision to stop apixaban after 6 months depends critically on whether the DVT was provoked by a transient risk factor or was unprovoked—provoked DVT can generally be stopped at 3-6 months, while unprovoked DVT typically warrants extended anticoagulation or at minimum reduced-dose therapy. 1

Risk Stratification Framework

Provoked DVT (Stop at 3-6 Months)

• Major transient/reversible risk factors (surgery, major trauma): Discontinue anticoagulation after 3-6 months of treatment 1, 2
• Minor transient risk factors (medical illness, travel-associated): Consider stopping after 3-6 months, though some guidelines suggest considering extended therapy 1
• Key principle: Patients with VTE provoked by transient risk factors typically do not require antithrombotic therapy after completion of primary treatment 1, 2

Unprovoked DVT (Consider Extended Therapy)

• First unprovoked proximal DVT: This is the most challenging scenario where the decision is "finely balanced" 1
• Recurrent unprovoked VTE: Strongly recommend indefinite anticoagulation 1
• Unprovoked isolated distal (calf) DVT: May stop at 3 months due to lower recurrence risk 3

Decision Algorithm After 6 Months

If Stopping Anticoagulation:

Step 1: Confirm the DVT was provoked by a transient factor that has resolved 1

Step 2: If unprovoked and stopping anyway, offer aspirin 1

• Aspirin reduces recurrent VTE risk by approximately 30% compared to placebo 1
• However, aspirin is much less effective than continued anticoagulation and should NOT be considered an alternative if the patient is willing to continue anticoagulation 1

If Continuing Anticoagulation:

Step 1: Switch to reduced-dose apixaban 2.5 mg twice daily 1, 4

• The 2021 CHEST guidelines and 2019 ESC both recommend reducing the dose after 6 months of full-dose therapy 1
• Reduced-dose provides 64 fewer recurrent VTE events per 1,000 cases compared to stopping, with only 6 additional major bleeding events per 1,000 cases 1
• Reduced-dose has 10 fewer bleeding events per 1,000 cases compared to full-dose, with only 2 additional VTE events per 1,000 cases 1

Step 2: Plan for indefinite therapy without a predetermined stop date 1

• Extended-phase therapy is defined as having no planned stop date 1
• Periodically reassess (every 6-12 months) for bleeding risk, treatment burden, and patient preferences 1

Factors Favoring Extended Anticoagulation

High-risk features that strengthen the case for indefinite therapy: 3

• Male sex (higher recurrence risk than females)
• Index event was PE rather than isolated DVT
• Positive D-dimer testing 1 month after stopping anticoagulation
• Persistent risk factors (active cancer, antiphospholipid syndrome, ongoing immobility) 1

Low bleeding risk also favors continuing anticoagulation indefinitely 3

Practical Implementation

For provoked DVT at 6 months:

• Simply discontinue apixaban without tapering 4
• No bridging therapy required 4
• Consider aspirin 81-325 mg daily if patient desires some ongoing prophylaxis 1

For unprovoked DVT at 6 months:

• Reduce apixaban from 5 mg twice daily to 2.5 mg twice daily 4
• Continue indefinitely with periodic reassessment 1
• If patient insists on stopping despite unprovoked DVT, offer aspirin as inferior alternative 1

Critical Caveats

Active cancer changes everything: 1

• Cancer-associated VTE requires indefinite anticoagulation regardless of provoked vs unprovoked status 1
• Recent evidence supports reduced-dose apixaban (2.5 mg twice daily) after 6 months in cancer patients, showing noninferior efficacy with less bleeding 5

Recurrent VTE is an absolute indication for indefinite anticoagulation regardless of whether the recurrence was provoked or unprovoked 1

Patient values and preferences must be incorporated through shared decision-making, particularly for unprovoked DVT where the risk-benefit balance is closest 1

Do not use patient-specific factors (BMI, renal function) to arbitrarily choose full-dose over reduced-dose for extended therapy—the default should be reduced-dose unless specific contraindications exist 1